Presentation description

Background:
Synovial sarcoma (SS) is a rare and deadly form of soft tissue sarcoma (STS), occurring primarily in children and young adults. Both children and adults with metastatic SS have overall survival (OS) rates at or below 30%.
Tyrosine kinases are crucial pieces of cellular machinery and mutations to their genes are highly associated with SS. Tyrosine kinase inhibitors (TKIs) are a new breed of promising drugs that target tyrosine kinase signaling cascades. Since the year 2017, multiple studies have shown the efficacy of a TKI called Anlotinib in treating subtypes of STS, including SS.
Methods:
Using a genetically engineered mouse model, we have sought to test Anlotinib’s efficacy against SS, as well as to investigate the pathways by which its effects are exerted. One group of mice were given the vehicle plus Anlotinib, whilst the other group received just the vehicle. After 122 days, data were collected, and some preliminary analysis has been done on the tumor size growth, overall lifespan, and the Kaplan-Meier survival rates.
Results:
None of the mice who received the vehicle solo survived till the end of the study, whilst two of those that received both Anlotinib and the vehicle did. The tumor growth rate was slower for the Anlotinib group and the overall survival rate for this group was significantly greater than for those mice that received only the vehicle.
Conclusion:
The data support the conclusions from prior studies, namely that Anlotinib is generally effective in slowing SS tumor growth in specific mouse models, as well as extending the OS of those mice. Further study is therefore warranted into interrogating the exact mechanisms and pathways of Anlotinib efficacy in tyrosine kinase signaling cascades, thus potentially leading to better SS treatments.